Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

Treatment of advanced non-small cell lung cancer (NSCLC) has evolved considerably over the past two decades, with improved survival outcomes in a significant proportion of patients due to the development of new effective systemic therapies. The refinement of the therapeutic approach with a molecularly-based strategy has led to unprecedented results in selected patient populations harboring actionable oncogene drivers (~20–25% of all NSCLC patients).